Natalizumab: Perspectives from the bench to bedside

Afsaneh Shirani, Olaf Stüve

Research output: Contribution to journalArticle

Abstract

Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to bedside perspective and the postmarketing experience standpoint. Natalizumab is a monoclonal antibody that inhibits the trafficking of lymphocytes from the blood into the central nervous system by blocking the adhesion molecule α4-integrin. Natalizumab was approved as a disease-modifying drug for relapsing remitting multiple sclerosis only 12 years after the discovery of its target molecule—a timeline that is rather fast for drug development. However, a few months after its U.S. Food and Drug Administration approval, natalizumab was withdrawn from the market because of an unanticipated complication—progressive multifocal leukoencephalopathy. It was later reinstated with required adherence to a strict monitoring program and incorporation of mitigation strategies.

Original languageEnglish (US)
Article numbera029066
JournalCold Spring Harbor Perspectives in Medicine
Volume8
Issue number12
DOIs
StatePublished - Dec 2018

Fingerprint

Pharmaceutical Preparations
Drug Approval
Leukoencephalopathies
Relapsing-Remitting Multiple Sclerosis
Lymphocytes
Neurology
Integrins
Multiple Sclerosis
Blood
Adhesion
Central Nervous System
Monoclonal Antibodies
Food
Molecules
Natalizumab
Monitoring
TimeLine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Natalizumab : Perspectives from the bench to bedside. / Shirani, Afsaneh; Stüve, Olaf.

In: Cold Spring Harbor Perspectives in Medicine, Vol. 8, No. 12, a029066, 12.2018.

Research output: Contribution to journalArticle

@article{b12309b7e42d419bafbd5e692935843d,
title = "Natalizumab: Perspectives from the bench to bedside",
abstract = "Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to bedside perspective and the postmarketing experience standpoint. Natalizumab is a monoclonal antibody that inhibits the trafficking of lymphocytes from the blood into the central nervous system by blocking the adhesion molecule α4-integrin. Natalizumab was approved as a disease-modifying drug for relapsing remitting multiple sclerosis only 12 years after the discovery of its target molecule—a timeline that is rather fast for drug development. However, a few months after its U.S. Food and Drug Administration approval, natalizumab was withdrawn from the market because of an unanticipated complication—progressive multifocal leukoencephalopathy. It was later reinstated with required adherence to a strict monitoring program and incorporation of mitigation strategies.",
author = "Afsaneh Shirani and Olaf St{\"u}ve",
year = "2018",
month = "12",
doi = "10.1101/cshperspect.a029066",
language = "English (US)",
volume = "8",
journal = "Cold Spring Harbor perspectives in medicine",
issn = "2157-1422",
publisher = "Cold Spring Harbor Laboratory Press",
number = "12",

}

TY - JOUR

T1 - Natalizumab

T2 - Perspectives from the bench to bedside

AU - Shirani, Afsaneh

AU - Stüve, Olaf

PY - 2018/12

Y1 - 2018/12

N2 - Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to bedside perspective and the postmarketing experience standpoint. Natalizumab is a monoclonal antibody that inhibits the trafficking of lymphocytes from the blood into the central nervous system by blocking the adhesion molecule α4-integrin. Natalizumab was approved as a disease-modifying drug for relapsing remitting multiple sclerosis only 12 years after the discovery of its target molecule—a timeline that is rather fast for drug development. However, a few months after its U.S. Food and Drug Administration approval, natalizumab was withdrawn from the market because of an unanticipated complication—progressive multifocal leukoencephalopathy. It was later reinstated with required adherence to a strict monitoring program and incorporation of mitigation strategies.

AB - Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to bedside perspective and the postmarketing experience standpoint. Natalizumab is a monoclonal antibody that inhibits the trafficking of lymphocytes from the blood into the central nervous system by blocking the adhesion molecule α4-integrin. Natalizumab was approved as a disease-modifying drug for relapsing remitting multiple sclerosis only 12 years after the discovery of its target molecule—a timeline that is rather fast for drug development. However, a few months after its U.S. Food and Drug Administration approval, natalizumab was withdrawn from the market because of an unanticipated complication—progressive multifocal leukoencephalopathy. It was later reinstated with required adherence to a strict monitoring program and incorporation of mitigation strategies.

UR - http://www.scopus.com/inward/record.url?scp=85066015536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066015536&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a029066

DO - 10.1101/cshperspect.a029066

M3 - Article

C2 - 29500304

AN - SCOPUS:85066015536

VL - 8

JO - Cold Spring Harbor perspectives in medicine

JF - Cold Spring Harbor perspectives in medicine

SN - 2157-1422

IS - 12

M1 - a029066

ER -